Three days after we exposed
Shkreli as the callous former hedge fund manager responsible for raising the price of Daraprim from $13.50 to $750 a pill, Shkreli announced on September 22, that he would lower the price of the life-saving medication in the next few weeks. Before Shkreli secured the exclusive rights to sell Daraprim, the drug only cost about
$1 per tablet.
During an
interview with NBC News over three weeks ago, Shkreli stated, “Yes it is absolutely a reaction — there were mistakes made with respect to helping people understand why we took this action, I think that it makes sense to lower the price in response to the anger that was felt by people.”
But in a
recent interview with Business Insider, Shkreli momentarily let the truth slip out when the heartless CEO rhetorically asked, “There have been hundreds of companies that have raised [their drug prices] higher, and they’re not rolling back their prices, so why should we?”
It is important to note that Shkreli would not be able to charge such exorbitant amounts for this drug if he weren’t backed by the US government. Turing Pharmaceuticals was granted a monopoly on the sale of Daraprim by the state. If anyone else attempted to make a similar drug for a lower amount, they would be met with the force of the state.
